Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis

Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC

Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC

Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC

Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC

Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, Fla.; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; and the Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC